Neuteboom, B
62  results:
Search for persons X
?
1

Therapeutic assessment of SEED: a new engineered antibody p..:

Muda, M. ; Gross, A. W. ; Dawson, J. P....
Protein Engineering Design and Selection.  24 (2011)  5 - p. 447-454 , 2011
 
?
2

Lipid microparticles as sustained release system for a GnRH..:

Del Curto, M.D. ; Chicco, D. ; D'Antonio, M....
Journal of Controlled Release.  89 (2003)  2 - p. 297-310 , 2003
 
?
3

Pharmacokinetics of recombinant human luteinizing hormone a..:

Porchet, H C ; Le Cotonnec, J Y ; Neuteboom, B..
The Journal of Clinical Endocrinology & Metabolism.  80 (1995)  2 - p. 667-673 , 1995
 
?
 
?
6

237 POSTER Leaving groups prolong the duration of 20S prote..:

Potts, B. ; Manam, R. ; Macherla, V....
European Journal of Cancer Supplements.  6 (2008)  12 - p. 74-75 , 2008
 
?
7

IAO01 Disease course after a first demyelinating attack in ..:

Neuteboom, R. ; Catsman, C. ; Boon, M....
European Journal of Paediatric Neurology.  11 (2007)  - p. 24 , 2007
 
?
10

Neurological deficits are present in syndromic craniosynost..:

Doerga, P.N. ; Rijken, B.F.M. ; Bredero-Boelhouwer, H....
European Journal of Paediatric Neurology.  28 (2020)  - p. 120-125 , 2020
 
?
13

Validated age-specific reference values for CSF total prote..:

Kahlmann, V. ; Roodbol, J. ; van Leeuwen, N....
European Journal of Paediatric Neurology.  21 (2017)  4 - p. 654-660 , 2017
 
?
 
1-15